Ben Lamm, co-founder and CEO of Colossal Biosciences, shared that investors are impressed with their rapid technological advancements, despite the company's non-revenue-generating status.
Colossal's work involves detailed genomic mapping of extinct species, with cell editing for a woolly mammoth underway, utilizing CRISPR and artificial womb technology.
Collection
[
|
...
]